Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
about
Interventions for mycosis fungoidesInterventions for mycosis fungoidesRole of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphomaPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaCutaneous T-cell Lymphoma.The influence of the coexpression of CD4 and CD8 in cutaneous lesions on prognosis of mycosis fungoides: a preliminary study.Ophthalmic abnormalities in patients with cutaneous T-cell lymphomaAllogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndromeA multidisciplinary approach to the diagnosis of cutaneous T-cell lymphomas.Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force ofManagement of refractory early-stage cutaneous T-cell lymphoma.Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndromeMycosis fungoides--a review of the management of 28 patients and of the recent literature.The diagnosis, staging, and treatment options for mycosis fungoides.Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.CD30 expression and proliferative fraction in nontransformed mycosis fungoidesLong-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides.Current and emerging treatment strategies for cutaneous T-cell lymphoma.Pruritus in cutaneous T-cell lymphoma: a review.Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group.Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging.Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection.T-cell receptor gene rearrangement studies as a diagnostic tool in lymphoproliferative skin diseases.Utility of bone marrow and liver biopsies for staging cutaneous T-cell lymphoma.Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course.The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma.Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement.Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10.CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients.Low expression of adhesion molecules in a case of cutaneous T-cell lymphoma.p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases.Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage.P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
P2860
Q24200749-8202BB64-5C34-487B-BA5D-E231BD773BDFQ24235242-71F44678-92FB-4505-94EB-E06CBDAB4CD5Q24626963-A94A3DBE-612F-41EE-823D-42D42F0CC9B1Q33386623-2AA03575-D520-4C2D-903A-937D8F1F3F1FQ33889220-88568BF5-CE30-45D0-A3FE-407BBA64A8F4Q34037897-3E8B10E3-F0B1-4222-9993-81CE1AC19514Q34163632-BF43C7D7-71B0-4F3E-ACC2-5E46753CB698Q34459010-14C1821D-6C65-4814-A159-DE3801C12797Q35971566-3636B85B-6BCA-428D-8D66-196CA9F5AAD7Q36174236-B46609E3-74BC-4122-8521-3A18568E8DD7Q36492318-71C042C9-043D-4247-8F11-62752ADFEE46Q36626781-037FD1B3-C0E8-4B07-A060-EE2A9E96F0DEQ36703890-DC1D396E-1986-4CB3-928E-B77207966AF8Q36771218-60356FDE-B7D3-4617-98D3-A6D73029FFCBQ36995610-1D611E56-6949-42D6-A412-0CB7FF1637E5Q37070128-1FFD291B-F441-4D81-89DD-19696D40A5E7Q37379370-A8F0EBC5-CC09-4C4B-AC42-14A8CA9A3581Q37585845-A62EE200-7C6B-4A55-AF34-02950E714C80Q37694527-D3466FA5-1E4B-4593-86D1-304FB1463183Q37979593-4FE944BE-0ADC-4C81-A27F-C39F6428CBE7Q38035410-7A14E016-C7ED-497D-9EE0-109600CF6806Q40275753-20B25B59-F3CB-4E26-9B1A-836B2E45EAF2Q40528057-9EB47EC6-A6AB-4968-9FE1-E5A07FA950C7Q40611205-A543CD82-19ED-4FA4-B34B-9457FC1884E3Q40739307-8895BA88-EA05-4D34-A86B-3112546E8D11Q40938340-170F39E9-D8CC-4BFA-8CDE-F3D74AA19C68Q41151101-0F69CFEF-EA93-4976-AA59-B406BAA8F035Q41261317-F0CDE305-45A3-4A29-A436-D23D6CECDE09Q41574252-7A53B3DC-D616-4139-A4CC-6838FC600072Q42435214-FA6D1E54-67F4-4465-AF40-FCE4574465B6Q43734642-696DD739-4203-45F8-BBA3-1690B974EE69Q46100557-213855A2-5F61-438D-ADF0-3C6CFD240187Q46951700-50DAE76B-9096-4157-8F2F-23149C64FF5FQ47763607-2BD97BFA-06EF-44AF-8895-9226F18A87ACQ52018886-813AB6F3-54CC-4740-836C-934274B362FDQ52051727-9C4B658C-F54C-400E-88E1-125FE7DA7468Q53417132-5B85631C-BB65-4A74-A136-3D2E89799760Q53475063-ADE453FF-C243-46A7-8310-E86180FEFAA7Q54033163-363AA31F-D8C8-4187-845B-403FFC191ED2Q54582099-2969104B-016B-4EE3-9D43-F16F15B38874
P2860
Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Histopathologic staging at ini ...... distinctive prognostic groups.
@en
Histopathologic staging at ini ...... distinctive prognostic groups.
@nl
type
label
Histopathologic staging at ini ...... distinctive prognostic groups.
@en
Histopathologic staging at ini ...... distinctive prognostic groups.
@nl
prefLabel
Histopathologic staging at ini ...... distinctive prognostic groups.
@en
Histopathologic staging at ini ...... distinctive prognostic groups.
@nl
P2093
P1476
Histopathologic staging at ini ...... distinctive prognostic groups.
@en
P2093
Fischmann AB
Glatstein E
Matthews M
Sausville EA
Schechter GP
P304
P356
10.7326/0003-4819-109-5-372
P407
P577
1988-09-01T00:00:00Z